Treats interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms…. Sold as Luzu. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Luliconazole (sold as Luzu), first approved Nov 14, 2013, with 2 new uses approved and 0 published complete response letters.
| Luliconazole | Part D | $82K | -2% | 209 |
| Luzu | Part D | $14K | +117% | 18 |
| Topical Lactoferrin and Luliconazole, Alone or in Combination, for Tinea CorporisTinea Corporis · Kafrelsheikh University | Not applicable | Recruiting | Nov 13, 2026 |
| Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual OnychomycosisOnychomycosis of Toenails · SATO Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Nov 10, 2026 |
| Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in DermatophytosisTinea Corporis, Tinea Cruris · University of Faisalabad | Phase 4 | Not yet recruiting | Nov 5, 2026 |
| Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor.Pityriasis Versicolor · PAEC General Hospital, Islamabad | Phase 4 | Not yet recruiting | Jan 12, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
